Investors

Home » investors » Corporate Information » Corporate Profile

Corporate Profile



Investor Tools

  • Email page
  • PDF view
  • Print view
  • Email Alert
  • RSS Feeds
  • Tearsheet
  • Mobile IR Site
  • Social Media Sharing
  • Email page
  • PDF view
  • Print view
  • Email Alert
  • RSS Feeds
  • Tearsheet
  • Mobile IR Site
  • Social Media Sharing

Stock Quote

  • NASDAQCNDO
  • Market Value ($M)61.44
  • Change ($)(0.03)
  • Change (%)(1.63)
  • Volume305,504
  • Stock Quote ($)1.81
As of April 17, 2014 - Minimum 20 minute delay.

Webcast
Coronado Biosciences TRUST-I Study Results Call
Monday, October 14, 2013
9:00 AM ET
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company’s two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.

Contact Information

Coronado Biosciences, Inc.
24 New England Executive Park
Suite 105
Burlington, MA 01803
Phone: (781) 652-4500
Fax: (781) 652-4545
info@coronadobio.com

Investor Relations
Lucy Lu, M.D., EVP & CFO
ir@coronadobio.com
(781) 652-4525
All Releases